Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Patent foramen ovale and cryptogenic cerebral infarction
Autore:
McGaw, D; Harper, R;
Indirizzi:
Monash Univ, Dept Med, Ctr Heart & Chest Res, Melbourne, Vic 3004, Australia Monash Univ Melbourne Vic Australia 3004 , Melbourne, Vic 3004, Australia Monash Med Ctr, Melbourne, Vic, Australia Monash Med Ctr Melbourne Vic Australia ed Ctr, Melbourne, Vic, Australia
Titolo Testata:
INTERNAL MEDICINE JOURNAL
fascicolo: 1, volume: 31, anno: 2001,
pagine: 42 - 47
SICI:
1444-0903(200101/02)31:1<42:PFOACC>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
ATRIAL SEPTAL ANEURYSM; TRANSIENT ISCHEMIC ATTACK; PARADOXICAL EMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; RISK FACTOR; TRANSCATHETER CLOSURE; THROMBOEMBOLIC EVENTS; SURGICAL CLOSURE; VEIN THROMBOSIS; STROKE PATIENTS;
Keywords:
cryptogenic; foramen ovale; paradoxical embolism; patent; stroke;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: McGaw, D Monash Med Ctr, 246 Clayton Rd, Clayton, Vic 3168, Australia Monash Med Ctr 246 Clayton Rd Clayton Vic Australia 3168 ustralia
Citazione:
D. McGaw e R. Harper, "Patent foramen ovale and cryptogenic cerebral infarction", INTERN M J, 31(1), 2001, pp. 42-47

Abstract

The patent foramen ovale (PFO) has been increasingly implicated in the aetiology of stroke, particularly in young patients with no other identifiablecause (cryptogenic stroke). The mechanism is by the passage of venous clots through the patent foramen into the arterial circulation, enabling cerebral embolism. Such patients with cryptogenic stroke and PFO are often treated with life-long anticoagulants or antiplatelet agents in an attempt to decrease the risk of a recurrence. Less commonly, surgical closure of the PFO has been undertaken in these patients. However, the recent evolution of closure devices that are delivered percutaneously by standard cardiac cathetertechniques now offer an alternative nonsurgical option. These alternative therapies are yet to be compared adequately. Two issues remain to be resolved. First, in determining appropriate therapy, patients with cryptogenic stroke may be divided into three groups: those with no PFO bur an alternativeunrecognized aetiology, those with an 'innocent' PFO and an alternative unrecognized aetiology and those with a causative PFO. The distinction between these groups clearly has important treatment implications. Second, the risk versus benefit of each available treatment modality must be determined for these different patient subgroups. These two issues require resolution before rational evidence-based treatment can be prescribed for patients withPFO and cryptogenic stroke.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/03/20 alle ore 00:49:38